Absci Corp

Clinical-stage biotech using generative AI and synthetic biology ("Integrated Drug Creation" platform) to design de novo antibody therapeutics. Lead asset ABS-201 is an anti-PRLR antibody in a Phase 1/2a HEADLINE trial for androgenetic alopecia with an interim PoC readout expected 2H 2026; the broader pipeline includes ABS-101 (anti-TL1A, IBD) and ABS-301/501 in oncology, plus partnered programs with Merck, AstraZeneca, and Almirall.